Company news

Viridian Therapeutics, Inc. news in 2022

Viridian Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease

December 20, 2022

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

November 27, 2022

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

November 13, 2022

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

November 13, 2022

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

November 7, 2022

Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

November 7, 2022

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

October 21, 2022

Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

October 11, 2022

Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering

August 24, 2022

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

August 14, 2022

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

August 14, 2022

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

August 7, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

June 22, 2022

Viridian Therapeutics to Participate in June Investor Conferences

May 31, 2022

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

May 11, 2022

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

May 2, 2022

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

April 5, 2022

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

April 3, 2022

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

March 20, 2022

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

March 13, 2022

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

March 9, 2022

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

March 2, 2022

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

February 13, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

January 30, 2022

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

January 3, 2022

Calls in 2022

Decks in 2022